Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy

Pain

Volumn 98, Issue 1-2, 2002, Pages 195-203

  Hammack, Julie E ^a   Michalak, John C ^b   Loprinzi, Charles L ^a   Sloan, Jeff A ^a   Novotny, Paul J ^a   Soori, Gamini S ^c   Tirona, Maria Tria ^d   Rowland Jr , Kendrith M ^e   Stella, Philip J ^f   Johnson, Joanne A ^g  

^a MAYO CLINIC   (United States)

^b Siouxland Hematology Oncology Associates   (United States)

^c MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^d Allan Blair Cancer Centre   (Canada)

^e Carle Cancer Center CCOP   (United States)

^f Ann Arbor Regional CCOP   (United States)

^g Cedar Rapids Oncology Project CCOP   (United States)

Author keywords

Cisplatinum; Nortriptyline; Peripheral neuropathy

Indexed keywords

CISPLATIN; NORTRIPTYLINE;

ADULT; ANOREXIA; ARTICLE; BAYES THEOREM; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEDATION; SLEEP TIME; SOMNOLENCE; STATISTICAL ANALYSIS; STATISTICAL MODEL; THORAX PAIN; URINARY TRACT DISEASE; VERTIGO; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CISPLATIN; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; NORTRIPTYLINE; PALLIATIVE CARE; PARESTHESIA; PERIPHERAL NERVOUS SYSTEM DISEASES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SLEEP; TREATMENT FAILURE;

EID: 0036299151     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(02)00047-7     Document Type: Article

References (40)

1. Problems of repeated significance testing
2. Controlling the false discovery rate: A practical and powerful approach to multiple testing
3. Completeness of reporting trial results: Effect on physicians' willingness to prescribe
4. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity
5. Pain measurement: An overview
6. Analgesic and antidepressive effects of low-dose amitriptyline in relation to its metabolism in patients with chronic pain
7. Sampling based approaches to calculating marginal densities
8. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double blind crossover study
9. Cisplatin neurotoxicity: The relationship between dosage, time and platinum concentration in neurologic tissues and morphologic evidence of toxicity
10. Measuring health-related quality of life
11. Interpreting treatment effects in randomized trials
12. The two-period crossover clinical trial
13. The course of neuropathy after cessation of cisplatin treatment, combined with ORG 2766 or placebo
14. Imipramine treatment of painful diabetic neuropathy
15. An open and double-blind cross-over study on the efficacy of clomipramine (Anafranil) in patients with painful mono- and polyneuropathies
16. Cisplatin neuropathy: Clinical course and neurophysiological findings
17. A general Gibbs sampling algorithm for analyzing linear models using the SAS system
18. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood
19. Efficacy of desipramine in painful diabetic neuropathy
20. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy
21. A systematic review of antidepressants in neuropathic pain
22. A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy
23. Procedures for comparing samples with multiple endpoints
24. Antidepressant-induced analgesia in chronic non-malignant pain: A meta-analysis of 39 placebo-controlled studies
25. A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability oft the tricyclic antidepressants chlorimipramine and nortriptyline in central pain
26. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
27. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain
28. The development of a method for assessing the quality of life of cancer patients
29. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action
30. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms
31. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double blind crossover study
32. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms
33. Graphical and analytical tools for the analysis of two-period crossover clinical trials
34. Incorporating quality of life measurement in oncology clinical trials
35. Measuring the quality of life of cancer patients
36. Cisplatin neuropathy: Clinical, electrophysiologic, morphologic, and toxicologic studies
37. Neuropathic pain: Aetiology, symptoms, mechanisms, and management
38. Pain relief in diabetic neuropathy: The effectiveness of imipramine and related drugs